Back to Results
First PageMeta Content
AL amyloidosis / Anatomy / Amyloid / AA amyloidosis / Proteopathy / Familial amyloid cardiomyopathy / Amyloidosis / Biology / Health


NEOD001 An Investigational Agent for the Treatment of AL Amyloidosis P
Add to Reading List

Document Date: 2014-04-27 21:59:39

Open Document

File Size: 461,70 KB

Share Result on Facebook

City

Dublin / /

Company

AL Amyloidosis P rothena Corporation / Prothena Corporation plc / Onclave Therapeutics Limited / P rothena Corporation plc / /

Continent

Europe / /

Country

United States / Ireland / /

/

Event

FDA Phase / /

Facility

Karmanos Cancer Institute / Memorial Sloan-Kettering Cancer Center New York / Tufts Medical Center / Stanford University Cancer Center / University of Pennsylvania Philadelphia / University School / /

IndustryTerm

biotechnology / owned subsidiary / abnormal light chain / /

MedicalCondition

light chain protein UNDERSTANDING AMYLOIDOSIS S / AL amyloidosis / organ dysfunction / AA amyloidosis / cancers / AL Amyloidosis P / disease / ystemic amyloidosis / rare progressive diseases / amyloidosis / diseases / systemic amyloidosis / /

Organization

the University of Pennsylvania / Memorial Sloan-Kettering Cancer Center New York / Tufts Medical Center Boston / Karmanos Cancer Institute Detroit / Stanford University / Boston University School of Medicine Boston / University of Pennsylvania Philadelphia / /

Person

Ying Hao / Heather Landau / Stephen Lo / Ann Birgin / Brendan Weiss / Jodi Jensen / Christiane Houde / David C Seldin / Jeffrey A Zonder / Theresa Neumann / Scott Weber / Mayo Clinic Rochester / Anthony Shelton / Morris A Gertz / /

/

Position

Principal Investigator / jjensen@tuftsmedicalcenter.org Study Director / /

Product

NEOD001 / investigational / EOD001 / /

ProvinceOrState

Alabama / Michigan / Pennsylvania / Massachusetts / /

Technology

antibodies / biotechnology / /

URL

http /

SocialTag